VEGFR1 (Vascular Endothelial Growth Factor Receptor 1) is an essential transmembrane receptor protein belonging to the tyrosine kinase receptor family. It is predominantly expressed on vascular endothelial cells, monocytes and macrophages, and mainly regulates angiogenesis, endothelial homeostasis and inflammatory immune responses in the human body. By specifically binding to VEGF ligands, this target activates downstream PI3K and MAPK signaling cascades, thereby modulating endothelial cell proliferation, migration, differentiation and vascular permeability to maintain normal vascular development and microcirculation balance. Abnormal activation or overexpression of VEGFR1 induces pathological angiogenesis, increases vascular permeability and promotes inflammatory cell infiltration, continuously driving tumor microenvironment remodeling, ocular vascular lesions and chronic inflammatory diseases. As a core target of anti-angiogenic targeted drugs, VEGFR1 can be specifically recognized and blocked by anti-VEGFR1 rabbit monoclonal antibodies to inhibit abnormal vascular proliferation and inflammation, which exerts precise therapeutic effects and has broad clinical application prospects in tumor and vascular disease treatment.